The Kaplan–Meier survival analysis demonstrated that the ovarian cancer patients with high E2F8 levels had poorer progression-free survival compared to that of the patients with low E2F8 levels (p = 0.032) (Figure 1C). This evidence concerns the gene E2F8 and ovarian carcinoma.